PDS Biotechnology Corp — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
In September 2026, PDS Biotech completed financing led by NantCapital and added Dr. Patrick Soon-Shiong to the Board. The company is refocusing on PDS0301 (tumor-targeted IL-12 immunocytokine), which showed 71.4% objective response rate and ~80% 24-month survival in Phase 2 mCRC with liver metastases (n=22 treated patients). A registrational Phase 3 protocol is in design; five data readouts are expected Q4 2026–Q2 2028 across prostate cancer, colorectal cancer, and Kaposi sarcoma. PDS0101 (HPV vaccine) is being deprioritized and the company is seeking strategic partnership or external funding for it.
Why this rating
Meaningful financing and board expertise (Soon-Shiong's FDA approval track record in immunocytokines) de-risk late-stage development. Phase 2 data appears clinically encouraging vs. benchmarks, but company is tiny ($60M market cap) and still pre-Phase 3. Execution risk remains high; clinical outcomes could change trajectory materially. Not yet transformational but significant strategic pivot with committed capital.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.